Concepedia

Chengxu Cui

CC

Statistics

Publications

15

Citations

1.5K

H-Index

13

Active since

2011

Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College(Current)

Anhui Medical University

Henan Cancer Hospital

Harbin Medical University

Third Affiliated Hospital of Harbin Medical University

Chengxu Cui is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in oncology, medicine, and pharmacology.

Publications per year

2011–2023

15

Publications

15

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Zixian Wang, Chengxu Cui, Jun Yao et al. · Cancer Cell · 2022 · 565 citations · Full text

, , +13

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Shukui Qin, Feng Bi, Shanzhi Gu et al. · Journal of Clinical Oncology · 2021 · 414 citations · Full text

, , +14

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Jianming Xu, Yi Li, Qingxia Fan et al. · Nature Communications · 2022 · 150 citations · Full text

, , +17

An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors

Yihebali Chi, Xiaokai Zhan, Hao Yu et al. · Chinese Medical Journal · 2013 · 106 citations · Full text

, , +8

An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma

Yan‐Xing Chen, Zixian Wang, Ying Jin et al. · Cancer Cell · 2023 · 48 citations · Full text

, , +16

1–5 of 15